METHODS OF ADMINISTERING RALTEGRAVIR AND RALTEGRAVIR COMPOSITIONS

摘要

The present disclosure is related to amorphous raltegravir and the solid oral dosage forms of amorphous raltegravir that are of lower dosage than the commercially available reference dosage form.